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Introduction
During the recent 4th European Summer School in
Clinical Pharmacology and Therapeutics in Vršac (2006,
September 16–20), organized by the European Association
of Clinical Pharmacology and Therapeutics (EACPT) and
the Clinical Pharmacology Section (CPS) of the Serbian
Pharmacological Society (SPS), as well as the International
Federation of Associations of Pharmaceutical Physicians and
the Serbian Association of Pharmaceutical Physicians it was
obvious that the status of clinical pharmacology still varies
widely from country to country in Europe 
1, 2. Namely, in
spite of many initiatives, its development in many countries
is too slow. The aim of this review was to present the devel-
opment and the state of the art of clinical pharmacology in
Serbia.
The historical background of the discipline
Clinical pharmacology originates from the development
of methods for formal testing of new medicines in men – es-
pecially from the randomized, controlled clinical trials. In
1932 Paul Martini published a monograph entitled "Method-
ology of Therapeutic Investigation", that summarized his ex-
perience in scientific drug evaluation and, probably after
which be was named the „first clinical pharmacologist“ 
3.
Although the resources, as well as expertise needed to de-
velop new drugs were primarily concentrated in pharmaceu-
tical industry, especially in the USA, academic clinical
pharmacologists, like Harry Gold and Walter Modell, also in
1930s, made important contributions to the design of clinical
trials 
4 . Yet, it was not until 1952 that Harry Gold, who was
considered to be the founder of the modern discipline of
clinical pharmacology, first formulated the need for the es-
tablishment of a separate discipline incorporating basic
pharmacology and clinical medicine, for which special kind
of investigators were needed 
5. Clinical pharmacology was
actually born as a result of the explosion of new and highly
active therapeutic drugs that were discovered between early
1950s and 60s. The concept of randomized, controlled clini-
cal trial, as the principal methodological tool, was defined as
any carefully planned, ethically acceptable experiment on
man, designed to answer a clearly defined question 
6, 7. Sev-
eral drug disasters, like thalidomide one, further urgented the
medical need to commensurate, in scientific terms, the bene-
fits of drug therapy relative to its risks
 8–10.
The World Health Organisation (WHO) study group re-
viewed the broad scope of activities of clinical pharmacol-
ogy, so in 1970 it became an established medical discipline
in a number of countries, especially the Nordic ones (Den-
mark, Norway and Sweden), the United Kingdom and the
United States 
11. They pointed aut the need for integrating
clinical pharmacology into the health service system and
making its services available according to the local condi-
tions. However, although individuals trained in clinical
pharmacology in the US were highly competent profession-
als, most of them worked in pharmaceutical industry, acade-
mies and governmental agencies, but none in the national
health care system, and, on the whole, their number was
rather small 
12, 13. Recently, in the report of the American
Board of Clinical Pharmacology, as an independent accred-
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1999 only 260 individuals were certified and acredited as
either clinical or applied pharmacologists 
14, most of them
being medical doctors, but also pharmacists or those who
have PhD degree in biological sciences.
Luckily, the situation in Europe used to be different
from the beginning, focusing both on research and well de-
fined health care services 
15, 16. One of the founder of the dis-
cipline in Europe, Professor Folke Sjöqvist said: “In order to
function well, a clinical pharmacologist needs to be needed.
He must, therefore, provide skills and know-how about drugs
that other members of medical profession lack or cannot
easily mobilize”.
  In order to achieve these goals, in 1986
WHO Working Group on Clinical Pharmacology in Europe
again set general principles, not only for teaching clinical
pharmacology, but also formulated guidelines on the role of
the discipline in health care delivery 
17, 18 .
The Serbian beginnings
The development of this discipline varied widely across
the Continent. Former Yugoslavia used to consist of six re-
publics and two autonomous provinces, each being responsi-
ble for its own health affairs. As a result of this, there existed
various development patterns of the discipline 
19. In Croatia,
for example, clinical pharmacology developed from the in-
ternal medicine, as an university department in Zagreb and
an unit in Split, had clinical responsibilities for inpatients and
outpatients facilities. In other republics, including Serbia, it
developed from basic pharmacology. One of the pioneers of
clinical pharmacology in former Yugoslavia, Professor
Božidar Vrhovac (University Hospital, Zagreb), in the very
same year when the mentioned WHO report of the experts
appeared 
11, informed medical public about the roles and
tasks of this medical discipline 
20. According to him, imple-
mentation of pharmacologic principles should benefit pa-
tients, decrease their exposition to potentially dangerous
medicines and, through the teaching of modern principles of
pharmacotherapy, promote the scientific application of
medicines.
Soon after that in 1974, it became a recognized medical
speciality in Croatia 
21. The need for the introduction of
clinical pharmacology as an official medical speciality was
also fully present in Serbia 
22–24. Some of the leading basic
pharmacologists in Serbia, like Professor Vladislav Varagić
(Medical Faculty, Belgrade), 
25–28 late Professors Milenko
Medaković and Branko Banić (Medical Faculty, Novi Sad)
22–24 and Professor Bogdan Bošković (Military Medical
Academy, Belgrade) 
29–32, clinically trained professionals as
late Professor Dragan Simić, internist (Clinical Hospital
Centre „Dr Dragiša Mišović“) 
33–35 and Professor Milan Sta-
nulovic 
22, trained in biochemistry (1962–1968) and paediat-
rics (1968-1974) became involved in the development of this
discipline. Concerning the Military Medical Academy, a
great contribution to the clinical pharmacology was given by
Professors of internal medicine Ratibor Mićić, Slavko Krstić
and Milan Popović, as well as colonel Svetomir Bečanović,
MD. This enabled further development of clinical
pharmacology, not only in the Military Medical Academy,
but through their engagement in various federal drug com-
missions, to its development in Sebia, as well.
The scientific and educational board of the Medical
Faculty in Novi Sad and its Department of Pharmacology
and Toxicology formally introduced the clinical pharmacol-
ogy as postgraduate programme (MSc, and PhD degree) in
1975 
24. Besides the youngest members of the Department,
these studies were successfully completed by many doctors
from the clinics or those employed in pharmaceutical indus-
try. However, first formally trained clinical pharmacologist
in Serbia was Prof. Milan Stanulović, who after his stays in
Great Britain, Nordic countries and the United States, passed
his examination at the Board of Croatia in Zagreb, in 1984.
An independent medical residency programme of clini-
cal pharmacology was established on the 22
nd of August
1981 at the Medical Faculty in Belgrade 
36. A 3-year training
of the graduated as MDs, consisted of 13 months spent at the
Institute of Basic Pharmacology, 9 months of formal lectures
and 14 months of clinical training. A shorter training pro-
gramme, clinical pharmacology subspecialty, lasting 18
months, also existed for specialists in internal medicine, an-
aesthesiology, general surgery, paediatrics, infectious dis-
eases and neuropsychiatry.
Although the formal prerequisite had existed for many
years, the role of clinical pharmacology, as a whole, and
especially in health care delivery was far from prominent
for a long time. As already stated, it was developed from
basic pharmacology in Serbia, and this fact influenced
greatly the development and professional activities of clini-
cal pharmacologists. In the beginning, most of the special-
ists were employed at the institutes of basic pharmacology,
as well as in industry, often without the real connections
with everyday clinical practice. On the other hand, most of
the sub-specialists have continued to perform their basic
professional activities after completing formal education,
without too many opportunities to apply new theoretical
and practical skills. Therefore, clinical pharmacology sur-
vived for a long time owing to enthusiastic work of  groups
or committed individuals who believed that it was worth
fighting. For example, drug utilisation and pharmacoepi-
demiology were introduced to the Institute for Pharmacol-
ogy, Toxicology and Clinical Pharmacology, Medical Fac-
ulty, Novi Sad, and these studies were among the first
pharmacoepidemiological ones at the territory of former
Yugoslavia 
37–39,
  although there were also successfully
planned and performed ones in the other university centers
40. Activities and publications in the field of the paediatric
clinical pharmacology, which some of the members of the
institute have performed, were also pioneering ones both in
the country, and abroad 
41, 42.
The main activities
During the early days, the main tasks of clinical phar-
macologists in Serbia were clinical trials, drugs committees
(DC), adverse drug reactions monitoring, pharmaco-
therapeutic information services and teaching and education
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Clinical pharmacologists participated in planning and
conductioning the controlled clinical trials, in collaboration
with clinicians. Military Medical Academy, for example, was
entitled by the Republic Secretariat of Health and Social
Welfare to carry out clinical trials since 1973 and all of its 4
clinical pharmacologists and one clinical pharmacist were
included in them in a ceratin way 
43–46. Through their activi-
ties in planning and organization of pharmacokinetic bioe-
quivalence studies and development of new analytical meth-
ods the Institute for Pharmacology, Toxicology and Clinical
Pharmacology at Medical Faculty in Novi Sad 
47, 48,
 National
Poison Control Centre, Military Medical Academy in Bel-
grade 
49, 50 and Department of Pharmacokinetics at the Fac-
ulty of Pharmacy in Belgrade 
51, 52 contributed to the devel-
opment of new generic products and gave new theoretical
solutions in pharmacokinetics.
The tradition of the DC in Serbia goes back to early
eighties of the previous century 
24. In the Military Medical
Academy, DC was founded on the 11 January 1980 and Pro-
fessor Bogdan Bošković, a pharmacologist and toxicologist,
was the first one who chaired it. It had 14 members. At the
Medical Faculty in Novi Sad it existed since September 1982.
It had 17 members and its first president was Professor Milan
Stanulović, pharmacologist and paediatrician. It actually de-
rived from the Committee for Pharmacotherapeutic Formu-
lary, founded in December 1977. Their tasks were, and still
are, the evaluation of applications for the controlled clinical
studies in hospitals, as well as their surveillance until the end,
reporting adverse drugs reactions, discussing drug utilisation,
defining hospital formularies, adopting clinical guidelines and
other activities through which clinical pharmacologists may
influence rational drug prescribing in a hospital.
Reporting adverse drug reactions is also one of the main
activities of clinical pharmacologists, and the Institute for
Pharmacology, Toxicology and Clinical Pharmacology in
Novi Sad was one of the most active Regional Centres in
Serbia 
53. On the other hand, the National Center for Adverse
Drug Reactions Monitoring (NCADRM), founded in 1994 in
Clinical Centre of Serbia, enabled all general conditions nec-
essary to apply the WHO Programme for adverse drug reac-
tions monitoring 
54. In the year 2000, it became a full mem-
ber of the WHO Uppsala Monitoring Centre (UMC). The
major tasks of NCADRM were detecting adverse drug reac-
tions and reporting them to all health care professionals, as
well as sending to UMC, especially those that were presented
as serious adverse reactions to drugs. There were also some
very good publications concerning adverse drugs reactions
which were valuable for clinical pharmacologists as well as
for other medical doctors and pharmacists interested in the
field of pharmacotherapy 
55–58.
Giving drug information to colleagues and other medi-
cal staff, as well as to patients, is also one of the very im-
portant tasks of clinical pharmacologists which can be ful-
filled in various ways. For example, the Institute for Pharma-
cology, Toxicology and Clinical Pharmacology in Novi Sad
has been publishing periodic publications „Drugs at the Mar-
ket“ from 1992, and it has entirely been transferred to elec-
tronic discs enabling efficient PC research 
59, 60. This also
helped the members of the institute very much to give the re-
quired information concerning drugs by the telephone to
anyone interested in, from the country, or abroad 
24. Prof.
Bogdan Bošković, from the Military Medical Academy, used
to write and publish a periodic publication „News in Phar-
macotherapy“ from 1980 to 2002 which offered the author’s
review of the most interesting and most important articles
concerning different fields of pharmacotherapy from the
most cited medical journals, for the year. There are also
available some other valuable publications concerning the
same issue in our country 
61–63, among which a monthly pub-
lished „Pharmacotherapy today“ edited by Ankica
Jelenković, MD, PhD, a specialist of clinical pharmacology,
deserves a special attention.
Teaching of clinical pharmacology in Serbia, as above
mentioned, started in 1975 in Novi Sad, as postgraduate pro-
gramme (MSc and PhD degree) 
24 as well as in 1981 in Bel-
grade,
  when it became an independent medical residency
programme 
36 resulting from understanding that it is the ne-
cessity and one of the three main roles of this medical disci-
pline 
18,  22,  64–66. Thanks to the efforts and enthusiasm of pro-
fessors Vladislav Varagić, Tomislav Kažić, Leposava Grbo-
vić, Ranka Samardžić and Milica Prostran, who led the post-
graduate studies in clinical pharmacology at the Institute for
Pharmacology, Clinical Pharmacology and Toxicology at the
Medical faculty in Belgrade, as well as Professors Milan
Stanulović, Ana Sabo and Momir Mikov at the Institute for
Pharmacology, Toxicology and Clinical Pharmacology at
Medical Faculty in Novi Sad, 90 clinical pharmacology spe-
cialists and subspecialists completed their professional edu-
cation until 2005 
67, 68.
The main challenge – recognition of clinical phar-
macology by National Health Service
Some of the leading members of the CPS of the SPS
also contributed to the development of clinical pharmacology
in Serbia. The section was founded in 1994 and here are
some historical milestones of it: Professor Tomislav Kazić
(President) and Professor Siniša Radulović (Secretary) acted
from 1994–1998 
69, Professor Milan Stanulović (President)
and Associate Professor Miloš P. Stojiljković (Secretary)
from – 2003 and Associate Professor Miloš P. Stojiljković
(President) and Assistant Professor Viktorija Dragojević-
Simić (Secretary) from 2003–2007, also as Acting President
from 2004–2006.
In spite of all, however, the development of this medi-
cal discipline have been too slow so far and, from the very
beginning, there have been difficulties in defining its per-
formance targets within the National Health Service (NHS).
Therefore, the current Presidency of the CPS of the SPS
launched the project of improving the status of clinical
pharmacology in our country and the first created, detailed
register of all clinical pharmacologists educatied in Serbia
and/or have been working in our country since 1981 
68.
Then, the role and impact of clinical pharmacologists
on health care in Serbia was investigated in two ways: by
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that 50% of the responders (60 clinical pharmacologists)
worked in the NHS and that the scope and quality of health
care services given by clinical pharmacologists were the best
in the tertiary health care hospitals with the independent de-
partments of clinical pharmacology 
68, 70, 71. The tradition of
the existence of the unit of clinical pharmacology, as well as
the efforts of establishing it in hospitals is very long at the
teritory of former Yugoslavia 
22, 69, 72–74.
This complies with the previously mentioned recom-
mendations of WHO
 according to which
 all the functions of
clinical pharmacologists, such as clinical pharmacology
service, training in clinical pharmacology and clinical phar-
macology research should be done at the hospital 
11. For this
reason the Technical Report of WHO clearly states that
„hospital beds and outpatient facilities must be available for
clinical studies, and clinical pharmacologist should be fully
responsible for his patients“. However, other authors have
considered that every clinical pharmacologist simply cannot
perform all the suggested functions, especially if he/she has
direct clinical responsibilities, and clinical pharmacologists
who cannot get their message to their colleagues in other dis-
ciplines will not be helped simply by running their own word
and particularly by practising general medicine 
15, 22, 75, 76.
However, everybody agree that in case of no separate de-
partment or unit available, it is the minimum requirement
that the specialist of this discipline has access to a patient
and is actively involved in patient care. One of the sugges-
tions of our prominent clinical pharmacologists, more than
20 years ago, was the model of the unit in large university
hospital with 10–20 patient beds, two to four responsible
specialists, one to three residents and several nurses specially
trained for organization of clinical trials, involvement in sur-
veillance of adverse drug reactions, drug consumption etc 
72.
Beside the small ward, unit should also have its office, small
laboratory, as well as outpatient room. Therefore, the de-
partments may have been established either as separate units,
or within existing departments of pharmacology or internal
medicine 
17, 22, 77. In Sweden, for example, a hospital provides
staff for the clinical pharmacology services, while medical
school provides position for research and teaching 
15. There-
fore, it is not generally defined how such facilities should be
organized, and national and local circumstances have to be
considered 
17, 78.
There are three academic departments in Serbia at the
moment: at the Medical Faculty in Belgrade, Novi Sad and
Kragujevac, all as joint departments with pharmacology and
toxicology. However, the first clinical pharmacology unit in-
side a hospital, which was founded in 1989 and still fully op-
erational, was situated in the Institute for Oncology and Ra-
diology of Serbia 
69, 79–81. Although long time has passed be-
fore the other ones have been formed awareness that im-
provement of patient care by promoting the safer and more
effective use of drugs can not be exercised without an effec-
tive service organization was permanently present. However,
during the last 10 years several clinical pharmacology serv-
ices were formed, all inside the tertiary health care hospitals
and as independent units: the Center for Clinical Pharmacol-
ogy in the Clinical Center of Kragujevac (since 1995) and in
the Clinical Center of Serbia (since 2003), the Center for
Pharmacotherapy in the Clinical Center of Niš (since 2004)
and Centre for Clinical Pharmacology in Military Medical
Academy (since 2005) 
68, 70, 71, 78, 82, 83 .
Presence and future
Both above mentioned field survey and the questionnaire
indicated that the following services were most often provided
by clinical pharmacologists in the Serbian health care system
by giving drug information, drug utilization analyses, taking
part in the work of DC and ethics committee, drug/patient
problem consultations, hospital’s drug formulary, auditing of
prescribing practice, taking part in drug clinical studies, con-
tinuing medical education, predispensing control of prescrib-
ing and therapeutic drug monitoring, as well as by drug sup-
plying and procurement management 
68, 70, 71, 78, 84. The broadest
spectrum of services was given by clinical pharmacologists
from the Center for Clinical Pharmacology at the Clinical
Centre of Kragujevac 
70. Therefore, our clinical pharmacolo-
gists are becoming more and more indispensable to hospital
managers and clinicians, but this is possible only through their
everyday involvement in clinical practice, as shown by the ex-
perience of the others 
15, 74, 85, 86. In May 2006 two regulations
on organization of health care facilities in our country were is-
sued by our Ministry of Health 
87, 88. Due to better under-
standing of the current role of clinical pharmacology in the
country, the introduction of independent CP service in tertiary
and secondary health care hospitals is foreseen, and, according
to these regulations, one specialist of clinical pharmacology
per 400 patient beds should perform his/her professional ac-
tivities, while in the clinical centers their number should be
1.25 per 400 patient beds.
We are convinced that the introduction of clinical
pharmacology into general district hospitals and enabling our
specialists to have service role in all mentioned areas, both in
secondary and tertiary health care facilities, will not only en-
sure further development of the discipline itself, but will also
contribute to the better health care system, as a whole. We
not only consider clinical pharmacology “too young to
die” 
86,
  on the contrary, agree but that the future of it, as
seamless continuation of basic one ought to be bright 
89, 90
and, the sooner we get this work done, the sooner we can see
the bright light at the end of the „tunnel
“ in which clinical
pharmacology has been for years in our country.
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